drugset
drugset / Trial / NCT02826382

Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041

NCT02826382 ↗

Phase 0 Completed 14 enrolled Five Eleven Pharma, Inc.
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

A phase1 study to demonstrate \[68Ga\]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.

Timeline

Start
2016-09-20
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-P15-041 Diagnostic / imaging agent — —

Indications

metastatic carcinoma in the bone prostate cancer